This site is intended for US audiences only.

This site is intended for US audiences only.

REVLIMID is a prescription medicine used to treat adults with follicular lymphoma (FL) or marginal zone lymphoma (MZL) in combination with a rituximab product, and who have previously been treated for their FL or MZL. FL and MZL are types of cancer of white blood cells called B-cell lymphocytes that are found in the lymph nodes and spleen. REVLIMID should not be used to treat people who have chronic lymphocytic leukemia (CLL) unless they are participants in a controlled clinical trial. It is not known if REVLIMID is safe and effective in children.

The REMS Companion App

Easily access the
Lenalidomide REMS program.

Download now

Patient and caregiver resources


Take a few moments to explore tools and other resources you may find helpful when learning about R2

Patient Brochure &
Treatment Tracker

R² (REVLIMID® [lenalidomide] + rituximab) patient brochure and treatment tracker DOWNLOAD

Medication Guide

Medication guide for REVLIMID® (lenalidomide) DOWNLOAD

Full Prescribing

Full prescribing information for REVLIMID® (lenalidomide) DOWNLOAD

Patient Conversation

Patient conversation starter R² (REVLIMID® [lenalidomide] + rituximab) brochure DOWNLOAD